Plain-English translation of NCT06938880 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new combination treatment made up of two medications: ZGGS18 and ZG005. The study wants to find out if these medications are safe to use together and whether they can help shrink advanced cancers in patients whose standard treatments have not worked. Researchers will carefully monitor your health and measure how much of the medication is in your bloodstream.
Many patients with advanced cancers like cervical cancer, liver cancer, and lung cancer run out of effective treatment options when standard therapies fail or cause too many side effects. This trial exists to see if this medication combination offers a new hope for patients in that situation.
You likely qualify if…
You likely don't qualify if…
In the first part of the study, researchers will test different doses of the medication to find the safest amount. In the second part, participants will receive that established dose every three weeks. You will have regular visits for blood tests, imaging scans, and health check-ups to monitor how the treatment is working and watch for any side effects.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Enrollment target
~60 participants
Started
May 2025
Primary completion
May 2027
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Siqi Jia
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.